Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

alarming rise in the incidence of disease, higher numbers of patients with complications and more frequent failures of standard antibiotic therapy.

Tolevamer is designed to bind and neutralize the toxins released by C. difficile that damage the intestine. A non-antibiotic approach has the potential to treat CDAD and reduce the number of disease recurrences, resulting in improved quality of life for the patient and significant savings to the healthcare system.

About the PACT Study

The PACT study, which involved more than 1,100 patients at approximately 300 sites in North America, Europe, and Australia, is the largest of its kind ever to be conducted for CDAD. In this trial, tolevamer was compared to metronidazole and vancomycin. Aside from testing tolevamer's efficacy, this was also the first large, rigorously designed, multi-center clinical study that will compare the efficacy of the current standards of care.

About Clostridium difficile

C. difficile proliferates in the setting of altered normal colonic bacterial flora, most commonly due to the administration of broad-spectrum antibiotics. Once established in the colon, C. difficile produces toxins that disrupt the intestinal lining, causing cell death and inflammation that result in diarrhea and colitis.

Earlier studies have shown that even after successful treatment with the current standard of care, approximately 20 percent of patients experience a recurrence of CDAD potentially requiring repeat hospitalization. In addition, a subset of patients with CDAD develop multiple recurrences of the disease, with symptoms that may persist for years.

About Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenue
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/27/2015)... , August 27, 2015 According ... Market by Type (Integrated, Standalone), by Deployment Mode (Web ... Physicians, Emergency Healthcare Service Providers), by Component - Global ... Systems Market is estimated at $501.1 Million 2014, and ... a CAGR of 7.6% from 2014 to 2019. ...
(Date:8/27/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), the maker ... abstracts featuring the use of ActiPatch®, its novel musculoskeletal ... Congress of the European Pain Federation EFIC®, ... 2015. The Company will also be exhibiting at the ... Bagnato , department clinical and experimental rheumatology from the ...
(Date:8/27/2015)... --  Americord Registry , a private cord blood ... banking company, announced today the launch of their ... website makes the expecting parent,s cord blood banking purchase ... checkout process. Logo - http://photos.prnewswire.com/prnh/20150827/261520LOGO ... this service difficult to purchase online. We want to ...
Breaking Medicine Technology:Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... Va., Nov. 16 As a two-time cancer survivor, Bill Still ... Sentara Cancer Network first-hand. When Bill,s prostate cancer ... group with the help of a community outreach nurse at Sentara ... care delivery system, he was largely on his own. , Bill ...
... , MAPLE GROVE, Minn., Nov. 16 ... Treatment of L ipoproteins and I nflammatory ... Journal of Clinical Lipidology . The objective was to ... and Lipitor (atorvastatin calcium) 10 mg/day, given alone and then ...
Cached Medicine Technology:Sentara Cancer Network Earns National Accreditation 2New Data: Cholesterol Management Analysis of Upsher-Smith's Slo-Niacin(R) Tablets in Combination with Lipitor(R) 2New Data: Cholesterol Management Analysis of Upsher-Smith's Slo-Niacin(R) Tablets in Combination with Lipitor(R) 3New Data: Cholesterol Management Analysis of Upsher-Smith's Slo-Niacin(R) Tablets in Combination with Lipitor(R) 4
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital ... 20 adult-only medical centers in the United States to receive international recognition for ... The Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent ... into the Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands ... Georgia State University study. , While most people don’t develop persistent depression after ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... & IoT Summit , scheduled for October 27-29, 2015 in San Jose, CA. ... the summit will primarily focus on the void that exists where battery development ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, the premium ... Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko competes in ... and recovery. , With a focus on technology and comfort, Zensah® has developed ...
(Date:8/27/2015)... CITY, Tenn. (PRWEB) , ... August 27, 2015 , ... ... LLC, DBA All Clear System. The agreement will enable both Johnson City, Tenn.-based firms ... All Clear System is a cloud-based safety product that caters to organizations in the ...
Breaking Medicine News(10 mins):Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4
... Ind., Feb. 27 Zimmer Holdings, Inc. (NYSE: ... N. Casper, Executive Vice President and Chief Operating Officer ... its Board of Directors. Thermo Fisher Scientific, the ... equipment, supplies and services used in life sciences, healthcare, ...
... System, as Inventor of the Month for February 2009SAN ... ADSK ) has named Cochlear Bone Anchored Solutions, a ... in the development and manufacturing of implantable hearing solutions, ... February 2009.Cochlear successfully used Autodesk Inventor software ...
... by Communion and Liberation: D A T E: Friday, February 27, 2009 ... Gowan Hall ( Nursing-Biology Building ), ... 620 Michigan Avenue NE , Washington , ... Different Way of Facing H.I.V. -- From Sickness and Despair to a New Life: ...
... a Highly Effective and Affordable New Option to Help ... Derma Sciences, Inc. (OTC Bulletin ... announced today that its first BIOGUARD Barrier Dressings have ... for marketing and distribution. BIOGUARD will offer surgeons, ...
... Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical ... company,s premier dental pharmaceutical product. OraVerse is the ... accelerates the return to normal sensation and function ... and unnecessary lingering soft tissue anesthesia following routine ...
... University of Pittsburgh Medical Center (UPMC) and Paphos Plantations Ltd. (PPL) - ... collaborating to develop a world-class health care center in Paphos, Cyprus, designed ... and foreign visitors to this Mediterranean island. , ... Pittsburgh, PA and ...
Cached Medicine News:Health News:Zimmer Holdings Names Marc Casper to Board of Directors 2Health News:Zimmer Holdings Names Marc Casper to Board of Directors 3Health News:Superior Sound Amplifies Quality of Life for the Deaf and Hard of Hearing 2Health News:Superior Sound Amplifies Quality of Life for the Deaf and Hard of Hearing 3Health News:Superior Sound Amplifies Quality of Life for the Deaf and Hard of Hearing 4Health News:Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology 2Health News:Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology 3Health News:Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology 4Health News:Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent 2Health News:Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent 3Health News:Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent 4Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 2Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 3Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 4
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
This probe coagulates bleeders while suction channel with trumpet valve simultaneously evacuates smoke....
Bair Hugger temperature management units are the only forced-air warming systems that can be used with an integrated, cost-effective method of fluid warming...
Medicine Products: